Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604890 · ClinicalTrials.gov registry record · Phase 1
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
A Phase 1 study, sponsored by BPGbio.
- Completed
- Registry status
- Phase 1
- Development phase
- 186
- Enrollment target
NCT00604890: Completed Phase 1 study, sponsored by BPGbio.
NCT00604890 is a Phase 1 study that has completed, run by BPGbio. The registered enrollment target is 186 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (210% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00604890, a Phase 1 study, has completed, sponsored by BPGbio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 186 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the treatment of superficial basal cell carcinomas by API 31510 topical cream. The study population will include one hundred and sixty (160) otherwise healthy male or female adults with one or more histologically confirmed superficial basal cell carcinoma lesions. One target lesion with an area of less than one inch will be designated for study treatment.
Primary Outcome
To determine the number of participants with a complete response, defined as a negative histological examination of the sBCC lesion at Week 10 (4 weeks post-treatment).
Interventions
- OTHER Placebo
- DRUG API 31510 3% Topical Cream
- DRUG API 31510 1.5% Topical Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
What the finished NCT00604890 record still lists
NCT00604890 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (210% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00604890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00604890 about?
NCT00604890 is a clinical study titled "Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma". The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the treatment of superficial basal cell carcinomas by API 31510 topical cream. The...
What is the current status of trial NCT00604890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 186 participants. The study started on 2008-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00604890?
The interventions under investigation include: Placebo (OTHER), API 31510 3% Topical Cream (DRUG), API 31510 1.5% Topical Cream (DRUG).
Who is sponsoring clinical trial NCT00604890?
This trial is sponsored by BPGbio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00604890's enrollment target sits among peer trials
186 291st of 2000 higher than 1,707 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia